Immune tolerance in hemophilia can be modulated by B cell activating factor

A group of scientists have just made a key discovery that could prevent and eradicate immune responses that lead to treatment failure in about one-third of people with severe hemophilia A. Hemophilia is the most common severe inherited bleeding disorder in men. The disease affects 1 in 10,000 males worldwide and results from deficiency of blood clotting factor VIII (FVIII). […]

Read more

Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerging, the coronavirus disease 2019 (COVID-19) pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study in Biomedicine and Pharmacotherapy reviews the potential for curcumin, a natural […]

Read more

Nanoparticles elicit neutralizing antibodies to diverse SARS-CoV-2 variants

Spike-protein-based nanoparticle vaccine candidates were retained longer in follicular dendritic cells and showed higher germinal center reactions in lymph node follicles compared to soluble spike protein vaccine. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected hundreds of millions worldwide since its emergence more than a year ago. The virus has also been mutating throughout the pandemic, with several […]

Read more

Antibody agents effective at neutralizing European, South African, and United States SARS-CoV-2 variants

Researchers in the United States have demonstrated the effectiveness of three antibody agents at neutralizing recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic. The team showed that one full-length antibody and two antibody domains each effectively neutralized pseudotyped virus containing key mutations found within the B.1.1.7 […]

Read more

New covalent and non-covalent SARS-CoV-2 inhibitors discovered in silico

With the onset of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it came to light that there were no specific and highly effective preventive or therapeutic agents against this virus. The result has been an enormous amount of studies reporting the efficacy or otherwise of novel drug candidates or repurposed drugs […]

Read more

Researchers test novel gene regulation approach to treat brain diseases

Researchers at the DZNE (Germany), at Massachusetts General Hospital (USA) and at the genomic medicine company Sangamo Therapeutics, Inc. tested a novel gene regulation approach to treat brain diseases such as Alzheimer's in laboratory studies. It leverages zinc finger proteins, which specifically bind to the DNA that codes for the protein Tau without altering it, thereby reducing Tau production in […]

Read more

IONTAS identifies novel SARS-CoV-2 neutralising antibodies

IONTAS Limited (IONTAS) and FairJourney Biologics S.A (FJB)., leaders in the discovery and optimization of fully human antibodies, have announced the identification of neutralizing antibodies, which bind to multiple emerging SARS-CoV-2 variants. The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalized COVID-19 patients, have identified potent neutralizing antibodies with distinct mechanisms of […]

Read more

Delaying second dose of Pfizer-BioNTech SARS-CoV-2 vaccine may be feasible in some cases

Researchers in Spain have conducted the most extensive study to date investigating the effectiveness of vaccinating healthcare workers with a single dose of the Pfizer-BioNTech vaccine to protect against coronavirus disease 2019 (COVID-19). The team says one dose of the vaccine induced a much stronger antibody response against the causative agent – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – […]

Read more

Is a single mRNA COVID-19 vaccine dose enough for recovered individuals?

Millions of people across the globe have been affected by the coronavirus disease 2019 (COVID-19) pandemic. Worldwide, researchers are working extensively to develop vaccines, facemasks, viral disinfectants, nasals sprays, and oral medicines to stop the spread of the respiratory pathogen, severe acute respiratory coronavirus 2 (SARS-CoV-2). Study: First dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in […]

Read more

Is a single mRNA COVID-19 vaccine dose enough for recovered individuals?

Millions of people across the globe have been affected by the coronavirus disease 2019 (COVID-19) pandemic. Worldwide, researchers are working extensively to develop vaccines, facemasks, viral disinfectants, nasals sprays, and oral medicines to stop the spread of the respiratory pathogen, severe acute respiratory coronavirus 2 (SARS-CoV-2). Study: First dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in […]

Read more
1 2 3 6